From the pages of AllergyWatch (R)

• Type of Material: Article
• Authors: Stanley Fineman, Emory University; Gerald Lee, Emory University; Todd Mahr, University of Wisconsin; Bradley E. Chipps, Capital Allergy and Respiratory Disease Center
• Language: English
• Date: 2021-03-26
• Publisher: Elsevier Science Inc.
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Published by Elsevier Inc. on behalf of American College of Allergy, Asthma & Immunology.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.anai.2021.01.005
• Title of Journal or Parent Work: Annals of Allergy, Asthma & Immunology
• Volume: 126
• Issue: 4
• Start Page: 444
• End Page: 445
• Grant/Funding Information: The authors have no funding sources to report.
• Keywords: Immunology; Life Sciences & Biomedicine; Allergy; Science & Technology
• Research Categories: Health Sciences, Human Development; Health Sciences, Public Health; Health Sciences, Health Care Management; Health Sciences, Immunology

Abstract

For this issue of “From the Pages of AllergyWatch,” I have selected 2 articles related to coronavirus disease 2019 (COVID-19) and asthma. The first review by Dr Lee from the November-December AllergyWatch postulates that the angiotensin-converting enzyme 2 (ACE2) receptors may be protective in our patients with allergic asthma and reduce the risk for hospitalization with COVID-19. The next article, reviewed by Dr Mahr from the September-October AllergyWatch, warns about stepping down controllers in pediatric patients with asthma during the pandemic. The last article, reviewed by Dr Chipps, evaluated the role of exhaled nitric oxide (eNO) as a guide to inhaled corticosteroid (ICS) stepdown decisions for our patients with asthma